Tuberculosis, Multidrug-Resistant
"Tuberculosis, Multidrug-Resistant" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tuberculosis resistant to chemotherapy with two or more ANTITUBERCULAR AGENTS, including at least ISONIAZID and RIFAMPICIN. The problem of resistance is particularly troublesome in tuberculous OPPORTUNISTIC INFECTIONS associated with HIV INFECTIONS. It requires the use of second line drugs which are more toxic than the first line regimens. TB with isolates that have developed further resistance to at least three of the six classes of second line drugs is defined as EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS.
MeSH Number(s)
C01.252.410.040.552.846.775
Concept/Terms
Tuberculosis, Multidrug-Resistant- Tuberculosis, Multidrug-Resistant
- Multidrug-Resistant Tuberculosis
- Tuberculosis, Multidrug Resistant
- Tuberculosis, MDR
- MDR Tuberculosis
- Tuberculosis, Multi-Drug Resistant
- Multi-Drug Resistant Tuberculosis
- Tuberculosis, Multi Drug Resistant
Below are MeSH descriptors whose meaning is more general than "Tuberculosis, Multidrug-Resistant".
Below are MeSH descriptors whose meaning is more specific than "Tuberculosis, Multidrug-Resistant".
This graph shows the total number of publications written about "Tuberculosis, Multidrug-Resistant" by people in Harvard Catalyst Profiles by year, and whether "Tuberculosis, Multidrug-Resistant" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1996 | 3 | 2 | 5 |
| 1997 | 1 | 1 | 2 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 0 | 1 |
| 2000 | 7 | 0 | 7 |
| 2001 | 8 | 1 | 9 |
| 2002 | 3 | 1 | 4 |
| 2003 | 7 | 0 | 7 |
| 2004 | 11 | 3 | 14 |
| 2005 | 11 | 2 | 13 |
| 2006 | 12 | 2 | 14 |
| 2007 | 10 | 2 | 12 |
| 2008 | 10 | 1 | 11 |
| 2009 | 11 | 1 | 12 |
| 2010 | 13 | 2 | 15 |
| 2011 | 17 | 4 | 21 |
| 2012 | 35 | 0 | 35 |
| 2013 | 29 | 2 | 31 |
| 2014 | 19 | 6 | 25 |
| 2015 | 27 | 0 | 27 |
| 2016 | 33 | 4 | 37 |
| 2017 | 27 | 3 | 30 |
| 2018 | 34 | 1 | 35 |
| 2019 | 20 | 5 | 25 |
| 2020 | 24 | 2 | 26 |
| 2021 | 3 | 0 | 3 |
Below are the most recent publications written about "Tuberculosis, Multidrug-Resistant" by people in Profiles.
-
Tuberculosis preventive therapy for children and adolescents: an emergency response to the COVID-19 pandemic. Lancet Child Adolesc Health. 2021 03; 5(3):159-161.
-
Drug susceptibility patterns of Mycobacterium tuberculosis from adults with multidrug-resistant tuberculosis and implications for a household contact preventive therapy trial. BMC Infect Dis. 2021 Feb 24; 21(1):205.
-
Culture Conversion in Patients Treated with Bedaquiline and/or Delamanid. A Prospective Multicountry Study. Am J Respir Crit Care Med. 2021 01 01; 203(1):111-119.
-
"Take the treatment and be brave": Care experiences of pregnant women with rifampicin-resistant tuberculosis. PLoS One. 2020; 15(12):e0242604.
-
New TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, India. Int J Tuberc Lung Dis. 2020 12 01; 24(12):1265-1271.
-
Prevention care cascade in people exposed to drug-resistant TB. Int J Tuberc Lung Dis. 2020 12 01; 24(12):1305-1306.
-
Clinical perspectives on treatment of rifampicin-resistant/multidrug-resistant TB. Int J Tuberc Lung Dis. 2020 11 01; 24(11):1134-1144.
-
Time for a change: considering regimen changes in analyses of observational drug-resistant TB treatment cohort data. Int J Tuberc Lung Dis. 2020 11 01; 24(11):1151-1155.
-
Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses. PLoS One. 2020; 15(10):e0240297.
-
Isoniazid Preventive Therapy in Contacts of Multidrug-Resistant Tuberculosis. Am J Respir Crit Care Med. 2020 10 15; 202(8):1159-1168.